Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07071090 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1
Started2025-06-30
View on ClinicalTrials.gov ↗

Amendment history

2025-07-18
Study Identification, Study Status v1
Study title-8 characters
A Phase 1 Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
2025-07-08
Original filing
This study employs a non-randomized, open-label design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC50292A tablets in patients with MTAP-deficient advanced or metastatic solid tumors. The study consists of two parts: dose escalation and dose expansion.
Trial Details
NCT Number NCT07071090
Lead Sponsor Heronova Pharmaceuticals
Conditions Solid Tumor Malignancies
Enrollment 32 participants
Start Date 2025-06-30
Primary Completion 2028-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-16